JINGXIN(SZ:002020) EBSCN·2025-09-01 06:13Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The commercialization of the core innovative drug, Dazisini, has achieved significant progress, with over 1,500 hospitals covered and a revenue of 55 million yuan in H1 2025 [2][4] - The company has seen a decline in revenue due to price reductions from centralized procurement policies, leading to a downward adjustment in net profit forecasts for 2025-2027 [4] Financial Performance Summary - In H1 2025, the company reported total revenue of 2.017 billion yuan, a decrease of 6.20% year-on-year, with finished drug revenue at 1.175 billion yuan, down 9.68% [1] - The net profit attributable to the parent company was 388 million yuan, a decline of 3.54% year-on-year, while the non-recurring net profit increased by 7.78% to 360 million yuan [1] - The operating cash flow was 393 million yuan, down 17.48% year-on-year, with an EPS of 0.46 yuan [1] Revenue and Profit Forecast - The revenue forecast for 2025 is adjusted to 4.1 billion yuan, with net profit estimates revised to 788 million yuan, reflecting a decrease of 13% from previous estimates [4] - The company is expected to see a gradual recovery in revenue growth, with projections of 4.58 billion yuan in 2026 and 5.068 billion yuan in 2027 [10] R&D Pipeline Progress - The company is advancing its R&D pipeline in the fields of mental health, cardiovascular, and digestive diseases, with several products in various stages of clinical trials [3][9]